---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-059530"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2024-07-05T23:59:59+00:00"
generated_at: "2026-05-31T23:22:04.448870+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# INmune Bio director Edgardo Baracchini resigns from board effective July 5, 2024

## Summary
- Baracchini had served on the board since August 2019.
- He was chairman of the Compensation Committee and a member of the Nominating and Corporate Governance Committee.
- Resignation is not due to any disagreement with company policies, operations, or practices.
- No replacement has been announced.

## SEC filing metadata
- accession: 0001213900-24-059530
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2024-07-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390024059530/0001213900-24-059530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390024059530/ea0208951-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-059530
- JSON: https://secwatch.observer/filing/0001213900-24-059530.json
- Plain text: https://secwatch.observer/filing/0001213900-24-059530.txt

## Key facts
- Executive change
  Edgardo Baracchini resigned as Director at Inmune Bio, Inc..
  - Action: resigned
  - Role: Director
  source text: On July 5, 2024, Edgardo Baracchini informed INmune Bio Inc. (the “Company”) of his resignation from the board of directors of the Company (the “Board”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390024059530/0001213900-24-059530-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.